Key Highlights

  • Third-quarter Revenue was USD 1,214 million, up 10% as reported and organically, led by Companion Animal Group growth of 10%.
  • Earnings per diluted share were USD 4.01, up 18% as reported and 22% on a comparable basis.
  • Placements of more than 1,900 IDEXX inVue Dx analyzers lifted the installed base of that platform to nearly 11,000 instruments.
  • Full-year EPS guidance rose to USD 14.96 to USD 15.16, a USD 0.25 increase at the midpoint.

Volume Growth Drives Double-Digit Revenue

IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported third-quarter 2026 revenue of USD 1,214 million, up 10% both as reported and organically. EPS of USD 4.01 included a USD 0.03 per share benefit from a non-operating gain on an Equity investment, USD 0.01 from share-based compensation tax benefits and USD 0.04 from currency changes, while absorbing Acquisition impacts.

CAG Diagnostics Recurring Revenue rose 11%, with international regions up 13% as reported and 14% organically and the U.S. up 10%. VetLab consumables grew 14% as reported and 15% organically, reference laboratory services grew 10%, and rapid assay products rose 1%. Capital instrument revenue was flat, while software, services and imaging systems grew 11% as reported. Water revenue rose 8% and livestock, poultry and dairy revenue rose 3%.

Margins Expand Despite Acquisition Costs

Gross Margin was 62.9%, up 110 basis points as reported and 90 on a comparable basis, supported by recurring revenue volume, productivity initiatives and net price realization. Operating Margin was 33.1%, up 100 basis points as reported and 60 on a comparable basis. Operating expenses rose 10% as reported and 11% on a comparable basis, funding commercial expansion and innovation while absorbing transaction costs.

Chief executive Mike Erickson pointed to inVue Dx with fine needle aspirate testing, the widening of IDEXX Cancer Dx into a multi-cancer panel and the acquisition of CoVet, an AI clinical assistant for veterinary teams, as drivers of customer value.

Outlook Moves Higher While Margin Guidance Eases

IDEXX raised 2026 revenue guidance to USD 4,741 million to USD 4,767 million from USD 4,700 million to USD 4,745 million, up USD 32 million at the midpoint, including USD 5 million from CoVet. Organic revenue growth guidance moved to 9.3% to 10.0%, and CAG Diagnostics recurring organic growth guidance to 10.3% to 11.0%.

The reported operating margin outlook was lowered to 32.1% to 32.3% from 32.3% to 32.5%, with the updated range including acquisition-related impacts. EPS guidance of USD 14.96 to USD 15.16 compares with a prior range of USD 14.69 to USD 14.94. Free Cash Flow is projected at 95% to 100% of net income, with capital spending of about USD 160 million, down from USD 180 million. Currency is projected to add about USD 0.25 to full-year EPS.

Factors to Watch Through Year End

On the call, management said U.S. organic CAG Diagnostics recurring revenue grew 9.6% in the quarter, and that the full-year recurring revenue outlook includes roughly 4% from global net price realization. IDEXX repaid USD 75 million of senior notes during the quarter.

An investor session at VMX in Orlando is scheduled for January 18, 2027, focused on the next point-of-care analyzer, IDEXX MultiCue Dx. Items to follow include premium instrument placements, Volume trends in the U.S. and the pace of acquisition integration.